The purpose of the current study is to design and synthesis of novel Mn2+ complex as an alternative to well-established Gd3+ chelates for use as a liver-targeting MR imaging agent. This new complex exhibits high R1 relaxivity (2.3 mM−1 s−1) than clinically approved Mn-DPDP® (1.6 mM−1 s−1) at 1.5 T. It is also kinetically much inert than that of Magnevist®. In vivo MRI enhancement pattern compares well with those of liver-specific MRI CAs such as Primovist® and Multihance®. It shows greater tumor detection in a liver tumor model with negligible toxicity in a clinical dose.
This abstract and the presentation materials are available to members only; a login is required.